Loading stock data…
RPRX
$55.63+0.77 (+1.40%)
After Hours$55.63+0.00 (+0.00%)· Last close Jun 9
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Royalty Pharma plc in the Healthcare sector is trading at $55.63. Wall Street consensus targets $59.25 (8 analysts), implying a +6.5% move over the next 12 months. The stock is currently near its 52-week high of $56.50, remaining 31.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$55.63
Potential Downside
0%
Whystock Fair Value$55.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.22%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.01%
Volume
Today's trading volume
3.59M
Recent News
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performance may have investors wondering how to approach the situation.
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean
Mattel is a global toy and entertainment company behind brands like Barbie, Hot Wheels, and Fisher-Price, serving families worldwide.
Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential
Why Royalty Pharma is Drawing Investor Attention Now Royalty Pharma (RPRX) has been getting more attention from investors recently, supported by its role as a buyer of biopharmaceutical royalties and as a funder of new therapies across areas like oncology, rare disease, and neuroscience. The stock has logged gains over the past week, month, and past 3 months. The company reports annual revenue of US$2.44b and net income of US$826.29m from its US royalty portfolio. See our latest analysis for...
3 Mid-Cap Stocks We Steer Clear Of
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]